Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.

Abstract

In the past decade, most studies on levetiracetam were conducted on patients aged > or = 4 years of age. The authors sought to assess the efficacy and safety of levetiracetam as an adjunctive treatment of children <4 years of age with refractory epilepsy. The mean levetiracetam dosage used on the 24 patients in this study was 38.85 mg/kg per day, and the mean duration of treatment was 40 weeks. During the study, levetiracetam was tapered off in 2 patients due to seizure worsening and was discontinued in other 2 patients due to unacceptable adverse effects. Levetiracetam therapy was effective in 58.3% of patients, with 20.8% achieving seizure freedom. Eight patients showed no obvious response and the remaining 2 patients showed divergent responses. Although adverse effects were seen in 37.5% of patients, all adverse effects were tolerable or resolved with time or discontinuation. Therefore, the authors conclude that levetiracetam treatment is effective and safe in young children with refractory epilepsy.

• Authors: Sixiu Li, Jie Cao, Nong Xiao, Fangcheng Cai
• Journal: Journal of child neurology (J Child Neurol) Vol. 25 Issue 5 Pg. 609-13 (May 2010) ISSN: 1708-8283 [Electronic] United States
• PMID: 19779208 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Levetiracetam
• Piracetam

Topics

• Anticonvulsants (administration & dosage, adverse effects, therapeutic use)
• Child, Preschool
• Drug Therapy, Combination
• Epilepsy (drug therapy)
• Female
• Humans
• Infant
• Levetiracetam
• Male
• Piracetam (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Seizures (drug therapy)
• Time Factors
• Treatment Outcome